The Central Social Insurance Medical Council (Chuikyo), an advisory board for the reimbursement system relating to public healthcare insurance, endorsed the listing of 16 new drugs with 12 ingredients at its general meeting on November 17th. The newly listed drugs included Takeda Pharmaceutical’s cell therapy Alofisel (darvadstrocel), with an NHI price of 5.62 million yen.

Alofisel was launched on November 30th, and on December 15, Takeda said that it has built a new manufacturing line for Alofisel at a plant in Osaka, western Japan.

Feel free to ask us any questions regarding NHI pricing method.  Contact us: hikari.matsuda@e-projection.com